Provided herein is a method for extracting polysaccharides, for example, β-glucan and sodium alginate, from a sample including a botanical product. The extraction can be carried out using a microwave assisted dual-solvent extraction followed by one or more membrane filtration steps.

The present invention relates to a method for decontaminating glucose polymers or the hydrolysates of the pro-inflammatory molecules thereof. Said method includes a) providing glucose polymers or the hydrolysates thereof, b) optionally, detecting or assaying the pro-inflammatory molecules in the glucose polymers or the hydrolysates thereof provided in Step a), and c) carrying out the following purifying steps: i. treatment using an enzymatic preparation having detergent properties and clarification properties; ii. treatment using a pharmaceutical-grade activated carbon with very high adsorption properties and “micropore” porosity; iii. optionally, treatment using a second activated carbon with “mesopore” porosity; iv. passing them over a macroporous adsorbent polymer resin having porosity greater than 100 Angstroms; and v. continuous ultrafiltration at 5 kDa.

A composition comprising an oat derived, salt precipitated β-(1,3)-(1,4) glucan having a molecular weight from about 150 kDa to about 250 kDa, a Mw/Mn ratio of about 1.0 to about 1.25, and a D3/D4 ratio of about 1.5 to less than about 2.0.

Provided are a β-1,3-1,6-glucan powder having high solubility in water, a glucan-containing composition using the powder or the like, a method for producing the β-1,3-1,6-glucan powder, an inclusion complex, a method for producing the inclusion complex, and a method for recovering a guest molecule. The β-1,3-1,6-glucan powder has a saturation solubility in water at 25° C. of from 1.0 to 20.0 % by mass. The β-1,3-1,6-glucan powder is such that in a particle size distribution of β-1,3-1,6-glucans, determined by subjecting the β-1,3-1,6-glucan powder to dynamic light scattering measurements, a particle size of a peak representing a largest volume fraction is in a range from 5 nm to 15 nm, and a volume fraction of a peak outside of the particle size range from 5 nm to 15 nm is 30 % or less of the volume fraction of the peak having the largest volume fraction.

Described herein is an isolated biological polysaccharide compound. The biological polysaccharide compound may be characterised by being isolated and having: glycosyl linkages comprising 1:3 linked glucopyranosyl residue of 65-95% wt and 1:6 linked glucopyranosyl residue of 5-25% wt; and a purity of 85-100% β-D-glucan; and a molecular weight of 0.5 to 2.2 MDa; and a TNF-alpha cytokine response in a human bioassay that is at least 1.5 times greater than a negative control TNF-alpha cytokine response in a human bioassay; and being essentially insoluble in aqueous solutions. In a further aspect, methods are described of treating skin by topical application of a vehicle containing the isolated biological polysaccharide to a skin site such as a wound or burn. A method of manufacture is also described.

The invention relates to compositions comprising citrus fibers and 1,3-β-D-glucans, specifically scleroglucan, for use in the manufacture emulsions or aqueous mixtures for use in topical formulations. The invention further relates to processes for manufacturing an emulsion, or aqueous mixture, or topical formulation and to uses thereof, especially in personal care products.

Disclosed are compounds, in particular based on polysaccharides, that are adsorbed on a cellulosic material, and relates in particular to the application of such compounds as reinforcing agent for cellulosic materials, in the wet and/or dry state. The compounds include a combination of at least one polysaccharide adsorbed on a cellulosic material, the polysaccharide including at least two different monosaccharide units, forming first and second monosaccharide units, the second monosaccharide units being branched on a chain including at least the first monosaccharide units, at least some of the second monosaccharide units being non-cyclic and bearing aldehyde functions, the aldehyde functions possibly forming hemiacetal functions with hydroxy functions of the cellulosic material.

The present teachings provide a method of making a yogurt product having increased thickness having the steps of providing milk; adding sucrose to the milk to form sweetened milk; contacting the sweetened milk with a glucosyl transferase to form an insoluble glucose polymer; inoculating with a starter culture; and fermenting to provide the yogurt product having increased thickness. Additional methods are provided.

A method of preparing a high yield of mushroom β-glucan is provided. The method includes: providing a liquid culture to culture the mushroom mycelium by fermentation, to increase the yields of the mushroom mycelium and polysaccharide, wherein the liquid culture comprises at least two ingredients selected from the groups consisting of glucose, trehalose, a dietary fiber and mannose or derivatives thereof; and rupturing the mushroom mycelium with a continuous multiple-ultrasonic equipment; and removing insoluble matters from the liquid culture. A method of preparing highly pure mushroom β-glucan powder and solution and the products thereof are also provided. By the method of the present disclosure, the yield of mushroom β-glucan is effectively increased, its activity loss is reduced, and the stability of product thereof is improved.

Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.